Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Hodgkin Disease 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Clinical Trials, Phase II as Topic × Clear all
NCT03919682 2021-08-26

BCED

Brigham and Women's Hospital

Phase NA Completed
1,203 enrolled
Breast

Breast Neoplasms

NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Servier

Phase 1/2 Completed
22 enrolled
Breast

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡